4. ďCompanies who are innovating are twice as likely to be growing
(ITI Business Monitor)
ďCompanies who invest in innovation demonstrate greater job
growth, employed better qualified people and are more likely to
export (NESTA)
ďCompanies who collaborate on innovation are more productive
than those that do not (OECD)
ďInvestments in innovation are responsible for 2/3 of UK
productivity growth (NESTA)
Importance of Innovation
5. What is Innovation?
The process that transforms your ideas into
commercial value.
It requires the execution of your ideas which address
specific challenges and achieve significant value
creation for both your business and your customers.
6. What is R&D?
⢠Research and Development plays a critical role
in the innovation process
⢠An investment in technology and future
capabilities which is transformed into new
products, processes, and services
10. Life & Health Sciences Sector in Northern Ireland
Employment 8,400
LHS average salary well above
the private sector median
2% of private sector employment in
NI
2014 Turnover
ÂŁ950m
80% in Pharma
10% in Medical Devices
10% Health & Wellbeing
LHS Sector accounts for
13% of NI Exports
65% of all LHS revenue is exports
Exports growing at 10% per annum
NI companies exporting to over 140
countries
170 Companies
Research Infrastructure
1000+ researchers in Centres of Excellence
HERD LHS Funding - ÂŁ175m
16,000 Students studying LHS subjects
4,000 LHS Graduate per annum
Academics
NI Health Services
66,000 employees
Budget - ÂŁ4.8bn
R&D Spend - ÂŁ15m
Health
11. Life & Health Sciences Sector in Northern Ireland
Growth over 3 years
Sector
Turnover
up 24%
Sector
Employment
up 21%
Industry
R&D Spend
up 90%
Sector
Exports
up 19%
12. Delivering Economic Benefits for Northern Ireland
Government Industry
Health Academia
Invest NI
Other
Government
Departments
HSC
5 Local Trusts
Acute Hospitals
Almac
Randox
Philips
Exploristics
Queenâs
University
Ulster
University
Life &
Health
Science
13. Delivering Economic Benefits for Northern Ireland
Government Industry
Health Academia
Invest NI
Other
Government
Departments
HSC
5 Local Trusts
Acute Hospitals
Almac
Randox
Philips
Exploristics
Queenâs
University
Ulster
University
Life &
Health
Science
14.
15.
16.
17.
18. Innovation Support Ecosystem
EUROPE NATIONAL LOCAL
Horizon
2020/
Enterprise
Europe
Network
EU
Structural
Funds
UKRI
Research
Councils
+
Innovate UK;
KTP, SBRI,
CRD, Catalysts,
Catapults
Government Departments
(DEL / DETI / DHSSPS /
DARD / DCAL)
Invest NI
Local
Authorities
HE / FE
Other
Support
Orgs*
Public
Research
Institutes
BEIS
* Includes InterTradeIreland, NISP, MATRIX, Private Sector etc
Patent Box
R&D Tax
Credits
19. A bit more about the âplayersâ & support
Innovation Vouchers
Technical Advisory Unit (TAU)
Design
Proof of Concept
KTP (in conjunction with KTN)
Grant for R&D
Competence Centres
Accelerator
NI Business Information
Access to Finance
Business Information Centre
QUB - Research and Enterprise
UU - Northern Ireland Centre for Stratified Medicine
UU - The Intelligent Systems Research Centre
UU - The Nanotechnology and Integrated Bio-Engineering
Centre
HSC Research and Development
North West Regional College
Catalyst Inc
Enterprise Europe Network
Innovate UK
20.
21. Invest NIâs role
⢠Delivery body for economic development
⢠Offering financial, capability development
and advisory solutions.
⢠22 international locations across Europe,
Asia-Pac, IMEA and Americas. 5 offices in
Northern Ireland
⢠Dedicated sector focused Client Teams
⢠Specialists in a wide range of business
disciplines
22. Delivering Success
Invest NI Commitment
⢠Strategic Priority
⢠Joined up approach
⢠Build on proven expertise
⢠Encourage collaboration
⢠Exploit International links
23.
24. Innovation
Vouchers
⢠A voucher is worth up to £5000 and is used by SMEs to allow them to
work with a Knowledge Provider
⢠Businesses may have a maximum of 3 vouchers for different projects,
but only one voucher at a time
⢠4 open calls for applications per year
25.
26. TAU & TDI support â advice & financial
⢠Investigating new technologies or processes
⢠Product & process problem resolution
⢠Product approvals e.g. VCA; TuV; UL; CE Marking
⢠Product/process improvement
⢠Management systems e.g. ISO9001; ISO27001; BRC;
⢠Intellectual Property e.g. Patents; Trademarks; licensing
agreements
27.
28. Current Sector R&D Focus
Medical DevicesOncology
Imaging/Pathology
Diagnostics
Diabetes
Clinical Trials
Neurodegenerative
Diseases
Infectious Diseases
29. Innovation Advisors (New to R&D)
ď 3 advisors for Grant for R&D;
ď Ciaran Mc Cartan
(Health, Life Sciences & Food)
ď Richard Pelan
(Engineering/ICT)
ď Robin Humphreys
(ICT/General enquiries)
30. Project Definition
ď Help plan and define the project. This can include:
ď A scientific and/or technical literature review
ď Defining the market opportunity
ď Defining the technical objectives and risks
ď Defining the costs of the R&D and understanding the financial implications
ď Determining the potential benefits
ď Funding capped at ÂŁ30k (ÂŁ15k for applying to IUK/H2020) of grant and a guidance of 5-10% of main
R&D project costs
ď ÂŁ24 hour labour rates
ď First region to get EU Commission approval
ď The actual employee(s) labour rate is vouched
31. Grant for R&D
ď Funding for Invest NI clients and potential clients
ď Support for technically risky projects
ď Ideas must be exploitable
ď Support for future work - not retrospective
ď Needs match funding
ď Support is discretionary - subject to Invest NI decision
32. Aspects of Successful Applications
Project
ď Level of Innovation
ď Technical Risk and R&D Challenge
ď Potential to create IP
ď Exploitation Potential
ď Company & Economic Benefit
Company / Applicant
ď Management Ability & Staff Expertise
ď Additionality
ď Viability
ď Track Record
33.
34. Competence Centres
ďCollaborative, strategic research, led by industry and resourced by qualified
researchers
ď Higher-risk, longer-term research with funding typically 5 years
ď Stimulate CRD and contribute to the âmarket focussed technology innovation
communitiesâ
ďCASE, Connected Health, NIACE (Advanced composites) and Agri-Food
35. Targeting External Funding
Enterprises that participate in National & EU projects:
ď Increase their R&D and innovation capability by tapping into a broader knowledge base
ď Gain access to national/international networks
ď Faster access to new markets and customers
ď Have access to qualified staff
ď Increase their reputation and visibility on a national/EU level
ď Receive attractive rates of funding - Horizon 2020 â up to 100% direct costs/25% overheads
36. Innovate UK
ďDirect UK Government Funding
ď Usually Collaborative
ď Mix of theme driven and open call opportunities
ď Knowledge Transfer Networks
ď Generous support rates
ď Competitive
37. Horizon 2020
Biggest EU Research and Innovation programme ever with nearly âŹ80 billion of
funding available over seven years (2014-2020).
Horizon 2020 is the financial instrument implementing the Innovation Union, a
Europe 2020 flagship initiative aimed at securing Europe's global competitiveness
Invest NI is a UK NCP for SMEs and can provide support for applications to the
SME instrument and Fast Track to Innovation
38. Queenâs University Belfast
Ulster University
Ulster University
Queenâs University Belfast
Ulster University
Ulster University
Queenâs University Belfast
Queenâs University Belfast & Ulster University & NISRA
Ulster University
39. A bit more about the âplayersâ & support
Innovation Vouchers
Technical Advisory Unit (TAU)
Design
Proof of Concept
KTP (in conjunction with KTN)
Grant for R&D
Competence Centres
Accelerator
NI Business Information
Access to Finance
Business Information Centre
QUB - Research and Enterprise
UU - Northern Ireland Centre for Stratified Medicine
UU - The Intelligent Systems Research Centre
UU - The Nanotechnology and Integrated Bio-Engineering
Centre
HSC Research and Development
North West Regional College
Catalyst Inc
Enterprise Europe Network
Innovate UK
40.
41. ⢠Aimed at proving the product and/or market.
⢠Concept Grants: Quarterly call for up to £10k grants to accelerate
product/solution validation and early prototype developments.
⢠Concept Plus Grants: Bi-annual call for up to £25k grants for
prototype/product refinement and further customer development.
⢠https://www.techstartni.com/grants
Proof of Concept â Techstart NI
61. What are Knowledge Transfer Partnerships?
1. Partner with an academic team
2. Employ a recent graduate
3. Deliver an innovative, strategically important product/process
4. KTP Programme running more than 40 years
5. More than 60 active Partnerships in NI (800+ across UK)
6. NI consistently the UKâs top performing region
62. More competitive, wealth
creating business
Well developed
âmanager of futureâImpact Research,
Teaching, Papers,
Placements etc Transfer &
âembeddingâ
of knowledge
Vital Knowledge
Support partnership fully
University/College
Significant Academic Benefit
Support Company, Project and Graduate
Transfer Knowledge and Capability
Business
Deliver Innovative Product/Process
Embed New Capability
Support and Develop Graduate
Associate (Graduate)
Stretch and Develop
Deliver project
Embed New Capability
Company Based Project
Innovative
Strategically Important
Company Missing Vital Knowledge
Knowledge Not Widely Available
Challenge and Reward for All 3 Partners
KTP Essential Features
More competitive, wealth
creating business
Support partnerships fully
Impact research teaching,
papers, placements etc
Vital knowledge
Transfer and
âembeddingâ of knowledge
Well developed manager of the
future
63. KTP Features
1. Projects can be 12 to 36-months in duration, typically 24 to 36-months
2. Academic team provide knowledge, expertise and facilities
3. Academic input, typically 0.5 days per week
4. Graduate and project based in company
5. More than 60% of graduates are retained by companies
64.
65. James Leckey Design Limited: Design and manufacture a range
of support devices for disabled children.
Project One: To embed the skills and knowledge necessary to
successfully integrate existing and emerging technologies into new
Leckey products and understand how data gathered can be used to
provide evidence for clinical practice within paediatrics.
Project Two: To develop an application of motivational learning
design methodologies to enhance and support customers in using
products for home therapy.
Case Study
66. iHelpr
The Knowledge Transfer Partnership between Inspire Workplaces and Ulster University has lead to
the development of iHelpr.
The iHelpr chatbot is embedded into a web based support hub. The user is guided through validated self-
assessments on topics such as stress, sleep and anxiety. Depending on the users score, they are directed
to the most appropriate self help resource within the support hub or towards face to face services, such as
counselling services or seeing their GP.
Case Study
Inspire Workplaces: A social enterprise that supports mental health in the workplace.
67. Total Cost
1. Graduate Salary (Pay ÂŁ18-36k pa) ÂŁ27 - ÂŁ45k
2. Graduate Development, Travel, Equipment ÂŁ6k
3. Access to university expertise and facilities ÂŁ33k
Total Package worth ÂŁ66 - ÂŁ84k
SME 67% Grant Support, Cost to Company ÂŁ22 - ÂŁ28k
Large Company 50% Grant Support, Cost to Company ÂŁ33 - ÂŁ42k
Jointly funded by Invest NI & Innovate UK
Typical Costs Per Year
68. Eligibility Summary
1. Ideally 4 employees or more
2. An innovative new product, service or process
3. A strong case for impact on net profit
4. A need to embed a new capability from an academic team
5. Challenging and rewarding project for the company, the associate and the academic
6. Local Advisers to help guide you through the process
74. Innovate UK: Funding and connecting
business innovation across the UK
Lorraine Acheson and Gordon Ford
23 October 2018
75. Innovate UK
Is the UKâs innovation agency.
Our mission is to accelerate UK economic growth
through funding and connecting
business-led innovation
throughout the UK
KNOWLEDGE ECONOMY SOCIETY
78. Innovate UK regional presence
across the UK, working to:
ď§ strengthen relationships
ď§ connect Innovate UK family with
regional stakeholders
ď§ ensure a coherent strategy across
the UK
ď§ https://datavis.innovateuk.gov.uk/app/
N. Ireland
Scotland
East Midlands
East of England
South East
North West
West Midlands
Wales
South West
North East,
Yorkshire &
Humber
86. Variety of health and life science
funding
Biomedical Catalyst
UK-China AMR
ÂŁ10M
Innovation Loans
Precision Medicine
Investment Accelerator
Genomics Manufacturing
Readiness
ÂŁ5M
Shaping the Future of
Precision Medicine (CR&D)
ÂŁ5M
Digital Health
Technologies Catalyst
ISCF challenges
OPEN Grant funding
Asthma UK/Innovate UK
Early Diagnosis
89. Industrial Strategy Grand Challenges
AI and Data
Economy
Ageing
Society
Clean
Growth
Future of
Mobility
90. Leading-Edge Healthcare / Medicines
manufacturing technologies
Batteries for clean and flexible energy storage
Robots for a safer world
Self-driving vehicles
Manufacturing and materials of the future
Satellites and space technology
ISCF Challenges â Wave 1 (ÂŁ683M)
91. Leading-Edge Healthcare / Medicines
manufacturing technologies
ISCF Challenges â Wave 1 (ÂŁ683M)
Medicines Manufacturing
Collaborative R&D
ÂŁ25m
Advanced Therapies
Treatment Centres
ÂŁ30m
Cell & Gene Therapy
Manufacturing Centre
ÂŁ12m
Medicines Manufacturing
Innovation Centre
ÂŁ13m
Vaccines Development
& Manufacturing Centre
ÂŁ66m
ÂŁ181m to develop first-of-a-kind technologies for the manufacture of
medicines to accelerate patient access to new drugs and treatments
Digital Health
Technology Catalyst
ÂŁ35m
Viral vector production
for cell and gene
therapies
ÂŁ5.6m
92. ÂŁ35m
over 4 years
Digital Health
Technology Catalyst
Funded through the Industrial Strategy Challenge Fund
National Information Board.
- address specific market failures so that the digital health sector can grow
- deliver transformative, cost-effective technologies to patients more quickly
Digital Health Technology Catalyst
Round 3 closes 31st October 2018
93. Digital Health Technology Catalyst, Round 3
Closes 31st October 2018
The aim of this competition is to speed up the development of new
digital solutions to healthcare challenges and grow the industry.
Projects must focus on the feasibility or development of digital health or
digitally-enabled medical technologies. These MUST have the potential
to achieve one or more of the following:
⢠improve patient outcomes
⢠transform healthcare delivery
⢠enable more efficient delivery of healthcare
These technologies may be designed to be used in both clinical or non-
clinical everyday settings.
Projects must be innovative and clearly demonstrate how they will
address needs of the healthcare system.
94. Overview of the DHTC Round 3 Competition
All DHTC projects must begin by April 1st
2019
Programme
Competitions
Total Funding available
DHTC 3
Feasibility:
Market and/or technical
feasibility
Collaborative R&D:
Industrial research and
experimental development
Up to ÂŁ1 million Up to ÂŁ8 million
Total Project Costs ÂŁ50k - ÂŁ75k Up to ÂŁ1 million
Project Duration Up to 12 months
SME led, Collaborative*Project Type
SME led, Single or
collaborative
12 to 24 months
*2 grant claiming organisations
Digital Health Technology Catalyst, Round 3
Closes 31st October 2018
95. Data to early diagnosis &
precision medicine
Healthy ageing
Next generation services
Audience of the future Quantum technology
Transforming
construction
Transforming food
production
Energy revolution
Second Wave of Challenges
96. CHALLENGE:
Combine the wealth of
data available with real
world evidence
⢠Genomics: WGS of
500,000 UK Biobank
Samples
⢠Digital innovation
Hubs: Link NHS to R&D
data and provide new
analytic tools for business
⢠Digital Pathology:
Radiology & AI Centres of
Excellence
Data to Early Diagnosis and Precision Medicine
(ÂŁ210m)
Create new products and services that will
diagnose diseases earlier and help clinicians
choose the best treatment for individual patients.
97. Healthy Ageing
The challenge is to develop new
products and services that offer
choice, meet their aspirations
and through better, more
effective care, support an
independent lifestyle as they
age. By working together, the
government and industry can
address the challenges of ageing
whilst capturing a growing global
market.
102. OPEN Programme
Open grant funding competition Round 3
Scope: âGame changing or disruptive innovationâ
Must have the potential for their idea or concept leading to significant return on investment
(ROI), positive economic impact, growth and scale-up of the business
Opens 24th September
Closes 14th November
ÂŁ20 Million is available
Projects lasting 6-18 months with total costs of ÂŁ25,000 - ÂŁ500,000
Projects lasting 19-36 months ÂŁ25,000 - ÂŁ2M
108. Agenda
1. KTN
2. Example of High Impact Intervention in Health
3. Future Developments
4. Collaboration is complicated
5. Questions
Ktn-uk.org @KTNUK
110. UK Research and Innovation Ecosystem
(one part of the ecosystem)
Academic Health Science Networks
Dept for Business, Energy and Industrial Strategy
Dept of Health
MedTech and In Vitro Diagnostics Co-operatives
National Institute for Health Research
NHS England
Office for Life Sciences
BEIS OLS DoH
UK Research
& Innovation
KTNInnovate UK
Research Councils
NHS (E, S, W, NI) NIHR
AHSNs MICs
NHS E
Ktn-uk.org @KTNUK
112. KTNâs Mission
(Who we are & why we exist)
KTN is the UKâs innovation
network.
Our mission is to deliver economic
growth. We connect people to
speed up innovation, solve
problems and find markets for
new ideas.
We bring together businesses,
entrepreneurs, academics and
funders to develop new products,
processes and services.
UK Economic
Growth
Businesses,
Entrepreneurs
and Investors
KTN The UKâs
Innovation
Network
Technologies,
Inventions and
Creativity
Ktn-uk.org @KTNUK
113. KTN Objectives
⢠Increase business led R&D
⢠Facilitate exploitation of R&D to capture more UK value from
innovation
⢠Increase collaboration between businesses (B2B) & between
businesses and the research base (B2R) for UK benefit
⢠Be the strategic partner of choice for innovation networking
⢠Provide breadth and depth of expertise for businesses
looking to innovate
Ktn-uk.org @KTNUK
114. Breadth of expertise
Chemistry & IB
Materials
Agri-Food
Health
Manufacturing
European &
International
Diversity
Design & Innovation
Access to Funding &
Finance
KT Advisers
Communications
Events
Finance and Ops
Emerging Tech
Enabling Tech
Creative & Digital
Infrastructure
Transport
Complex Systems
115. ⢠Discovery and development
⢠Scale-up and manufactureMedicines
⢠In vitro technologies (including wearables)
⢠Implantable technologiesMed Tech
⢠Systems for diagnosis/remediation of disease
⢠Electronic records in health & careDigital
KTN Health Priorities
Ktn-uk.org @KTNUK
116. KTN Fit: Enabling âthe Worldâs most
innovative economyâ*
ââŚdo more to address some of the frictions in the
system to support collaboration and the flow of
knowledge between research base and industry,
accelerating the path to market.â
*Industrial Strategy White Paper 2017
117. Example of High Impact
Interventions in Health
Ktn-uk.org @KTNUK
118. Prevention
of Disease
Identification
of Disease
Treatment of
Disease
Public
Health
Vaccination
Health
Monitoring
Non-
specific
Chronic Disease
Acute
Disease
Medical
Technology
Lifestyle
change/Wellness â
often Digital
Medicines
What is Health
Ktn-uk.org @KTNUK
119. Cervical Screening and Vaccination
0
http://www.ncin.org.uk/publications/data_briefings/cervical_incidence_and_screening
CIN I CIN II CIN III Cervical CancerNormal
Biomarker
PAP smear test Diagnostic test
Treatments Intervention
Ktn-uk.org @KTNUK
120. Cervical Screening and Vaccination
0
http://www.ncin.org.uk/publications/data_briefings/cervical_incidence_and_screening
16.24,132
16.2
2,620
9.3
2,369
8.3
1988 20081998
Vaccination
⢠187m doses worldwide
⢠130 countries
⢠90% reduction in HPV infections
⢠45% reduction on low grade
cytology
⢠85% reduction in high grade
cytology
Eradication of HPV associated
cancers by between 2040
and 2050
Ktn-uk.org @KTNUK
121. Prevention
of Disease
Identification
of Disease
Treatment of
Disease
Cervical Screening and Vaccination
Developments
Changes to screening process
Changes to vaccine formulation
HPV typing
Focus on high risk age-groups
Novel ablative
Advanced Therapeutics
Ktn-uk.org @KTNUK
122. Prevention
of Disease
Identification
of Disease
Treatment of
Disease
Future of Health
Driven by ISCF
Whole Genome Sequencing
Longitudinal Cohort Studies
Multi âomics
New Diagnostic Tests
Cancer Immunotherapy
Advanced Therapeutics
Ktn-uk.org @KTNUK
125. Innovate UK
(UKRI)
KTN
International National Regional
OLS
DH
NIHR
MICs
RCs
Trade Assoc.
NICE
Research
Charities
CompaniesCompaniesCompanies
AHSNs
Medilinks
One Nucleus
BioNow
OBN
BioCity
Universities
Hospitals
Academics
Clinicians
European
Commission
FCO-SIN
European
Networks (EBN)
FDA
DIT - Healthcare U
K
LEPs
MHRA
EEN
EEN
Ktn-uk.org @KTNUK
131. Develop specific
interventions for diverse
markets
Foster a collaborative
approach wherever
appropriate
Establish and maintain the
UK as the best place to
drive health innovation
Understand
the innovation
landscape
Companies
SMEs
Large
Companies
Stakeholders
Numerous
Ktn-uk.org @KTNUK
135. Relevance to Your Business
You heard about what the future holds â now letâs turn to your
business
What do the future trends mean to you?
136. Relevance to Your Business
â˘Will your current product/service deliver your
customer needs?
⢠What modifications would be beneficial?
⢠What are the economic/social benefits of your product/service
suite?
137. Relevance to Your Business
â˘Who will your customers be and how will you
engage with them?
138. Relevance to Your Business
â˘Who will your competitors be?
⢠What do you know about them and their future-proofing?
139. Relevance to Your Business
â˘Do you have the partners you need or will you
need new partners?
⢠Who will they be?
⢠Will your funding sources change?
143. Funding for Innovation
in Life & Health Sciences
Wifi: TitanicGuests
Twitter: @InvestNI
@innovateuk
@KTNUK
Hinweis der Redaktion
2 more international offices to be opened
Invest NI Commitment
Strategic Priority
importance recognised at top level
Government Strategies aligned
Focus and investment already happening
Joined up
Business/academia/clinicians/government
HSC integrated
Invest NI single access point for industry and R&D
Deep Specialism in this area
Business and clinical expertise
Technical expertise and infrastructure
Experience in collaboration
International links
Connected and accessible
And at Innovate UK we are confident in our ability to meet the challenge and take advantage of the opportunity
2017 has been the 10 year anniversary of Innovate UK and we have been proud to have looked back at the achievements over that decade
11,000 projects, 8,000 organisations, 70,000 jobs created, ÂŁ7.30 return on investment
In the last year alone (FY 16/17) we supported nearly 2,900 organisations, across 1,100 projects, 76% SMEs
60% of our core grant funding goes to SMEs
10 regional managers based around the UK
Strengthening relationships
Identifying regional hubs
Engaging affiliate funders to enhance support for businesses
KTN â at the centre of our connecting work â connecting companies to customers, supply chains, collaborators
EEN â international network â connect businesses to international opportunities
Knowledge transfer partnerships connect academia to business â similar to Fusion programme run by Intertrade Ireland
Over 600 partner organisations in 66 countries
Our Catapult Network has partnerships in over 24 countries.
We are very proud of our Catapults - our national technology and innovation centres.
They have a vital role to play in developing the Industrial Strategy.
The Catapults have over ÂŁ850 million in open access facilities available to companies and universities seeking support in their work.
Catapults and their centres are based all over the UK â from the Digital Catapultâs regional centre in Belfast to the headquarters in South Wales for the newest Catapult in Compound Semi Conductors.
The Catapults have supported 3,000 SMEs in almost 2,500 industrial collaborations
And they have over 600 academic collaborations across the Network.
Catapults are also active in talent development.
For example the Cell and Gene Therapy Catapult has a âtraining through immersionâ policy with a healthy transition of staff to and from the growing industry.
While the High Value Manufacturing Catapult has trained over 900 apprentices in the past year and is developing new degree level apprenticeships with the University of Sheffield and Sheffield Hallam University.
This is an overview of the variety of funding opportunities we have offered this year.
Innovate UK is delivering on six challenges from ISCF wave 1, with a total investment of
Innovate UK is delivering on six challenges from ISCF wave 1,
Background to the competition. This is round 3 of the The Digital Health Technology Catalyst which is a ÂŁ35m funding programme being run over 4 years and is funded through the Industrial Strategy Challenge Fund. It was originally a recommendation of the Accelerated Access Review, the independent review, chaired by the Welcome Trust and is aligned with NHS Englands 5 year forward view. The catalyst has been designed to support the development of innovative health solutions underpinned by digital technology. The goals are also aligned with those of the National Information Board and the UK Life Sciences Strategy specifically to:
address specific market failures so that the digital health sector can grow
deliver transformative, cost-effective technologies to patients more quickly
The Digital Health Technology Catalyst has been designed to support SMEs in developing innovative health solutions underpinned by digital technology. The aim of this programme is to speed up the development of new digital solutions to healthcare challenges and grow the industry.
As you know only too well, digital health is evolving at such a rapid pace this is having a profound impact on healthcare delivery. The DHTC is designed to further support the growth in new digital health solutions that have the potential to:
improve patient outcomes;
improve access to healthcare;
make more targeted and personalised health interventions;
transform service delivery;
and to deliver new treatments
We are open to both clinical or non-clinical proposals, but proposals will need to clearly demonstrate how they will address the needs of the healthcare system.
Now Iâd just like to run through some key elements of the call.
bs â linking routine NHS data with rich data from R&D programmes, providing analytic tools and informatics support for businesses alongside local access to federated UK-wide data;â
Digital Innovation hubs: Delivered by Health Data Research UK
Catalysts are designed to support an SME along the journey from an initial idea through to the point at which they can attract private sector investment without the need for grant funding. The Biomedical Catalyst will support the development pathway through to a product tested in humans and is divided up into 4 awards which support progression along that pathway.
Each award has a different scope, so applicants must meet the scope of the individual award, as well as the overall scope of the Biomedical Catalyst.
We donât run competitions for every award in every round of the Biomedical Catalyst. In Round 4, we are running competitions only for the Primer and Late Stage awards. The next slide sets out the specific scope of these in more detail â this slide just gives an overview. Now that we have the Primer award as an intermediate step between Feasibility and the Major Awards, the Early Stage award has been repositioned to cover those projects which are on their home run towards completion of a pre-clinical data package, so that if they complete this project successfully they will be in the perfect position to continue with a Late Stage award.
The Biomedical Catalyst is a programme of funding that has supported industrial research since 2012.
And it has been in collaboration with the Medical Research Council
It aims to support companies through each of the stages of innovation development so that they can bring products and services to market quicker.
And to do this there are 4 types funding awards reflecting progress through different stages of development. And each of these awards have different eligibility criteria.
The processes for applicant are also different. For feasibility and primer, awards are based solely on your assessment of the application and the scores that you give.
For early stage and late stage, the scores that you award are used to identify quality applications. We then take those applications that achieve a quality threshold and invite those applicant to attend a panel interview. The panel ultimately decides which of those projects get funded. Your feedback is seen by both successful and unsuccessful applicants. For late stage your feedback is essential here for helping both the applicant identify what information is lacking from their application and for helping the panel in their decision making.
In this competition, Round 2, we invited applications to the Primer and Late Stage Awards.
Each award shares the broad scope of the Biomedical Catalyst, that is the development of an âinnovative solution to a health and care challengeâ.
This means that he Biomedical Catalyst embraces:
Prevention as well proactive management
And innovative approaches for managing health, not just illness;
The scope includes development of diagnostics as well as treatments.
Emphasis that loans are for projects that are:
closer to market
about the business as well as the project
Ready to scale up
Innovation Loans sit as part of the continuum from research through to commercialisation â they are a new IUK offer to innovative companies, not a replacement for existing activity.
3.7% - well below the market rate of interest
Welcome questions (if time allows)
Innovate UK is here to help UK businesses to build the industries of tomorrow
And to grow the UKâs position globally in R&D.
Any further questions to be directed at Customer support: support@innovateuk.gov.uk or 0300 321 4357
The Knowledge Transfer Network is grant funded by Innovate UK to connect you in the following ways:
Â
Our innovation specialists can personally meet or talk with your company to map out your needs and capabilities and to make introductions.
We host thematic cross-sector events across the UK that you can attend to build connections.
We can send you bespoke news and digital content.
The Knowledge Transfer Network Ltd also works with a variety of other partners to contribute to UK growth through innovation